Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.

Neuro-oncology - 2 Nov 2022

Iorgulescu J Bryan, Sun Chuxuan, Neff Corey, Cioffi Gino, Gutierrez Catherine, Kruchko Carol, Ruhl Jennifer, Waite Kristin A, Negoita Serban, Hofferkamp Jim, Tihan Tarik, McLendon Roger, Brat Daniel J, Ostrom Quinn T, Barnholtz-Sloan Jill S

Abstract excerpt

BACKGROUND: Selected molecular biomarkers were incorporated into the US cancer registry reporting for patients with brain tumors beginning in 2018. We investigated the completeness and validity of these variables and described the epidemiology of molecularly defined brain tumor types. METHODS: Brain tumor patients with histopathologically confirmed diagnosis in 2018 were identified within the Central Brain Tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Glioblastoma

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to United States

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 35460555
DOI: 10.1093/neuonc/noac113
PMCID: PMC9629432

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.PMID 35460555Read ↗

Incorporating Advances in Molecular Pathology Into Brain Tumor DiagnosticsSemantic proximity Read ↗

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumorsSemantic proximity Read ↗

Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system.Semantic proximity Read ↗

cIMPACT ‐ NOW update 11: Proposal on adaptation of diagnostic criteria for IDH ‐ and H3 ‐wildtype diffuse high‐grade gliomas and for posterior fossa ependymal tumorsSemantic proximity Read ↗

2016 World Health Organization Classification of Central Nervous System Tumors.Semantic proximity Read ↗

Clinical impact of molecular profiling in rare brain tumors.Semantic proximity Read ↗

National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.Semantic proximity Read ↗

Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas.Semantic proximity Read ↗

Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?Semantic proximity Read ↗

A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnosticsSemantic proximity Read ↗

Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas.Semantic proximity Read ↗

Molecular Testing of Brain TumorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.